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htcense.Abstract Background: Malignant pleural mesothelioma (MPM) is a highly aggressive tumor with
poor survival rate. It is difﬁcult to diagnose MPM at an early stage. Soluble mesothelin remains the
best available biomarker for MPM, however the lack of sensitivity for early stage disease provides a
motivation for the search of an additional marker that could be combined with mesothelin for early
malignancy detection.
Aim of work: The aim was to evaluate the diagnostic value of soluble mesothelin and osteopon-
tin both in blood and pleural ﬂuid of MPM patients and to assess whether combination of these
markers could improve the diagnostic accuracy of mesothelin.
Methodology: In this study mesothelin and osteopontin were measured by ELISA method in 197
samples (123 blood and 74 pleural) obtained from 123 participants, divided into 4 groups: 38 MPM
patients, 24 patients with metastatic pleural effusion (Mets) of various carcinomas, 29 patients with
hydrothorax and 32 healthy asbestos exposed subjects. Receiver operating characteristic (ROC)
curves were generated to compare the diagnostic capability of these biomarkers. Combination of
markers was done through logistic regression analysis.
Results: The median blood and pleural levels of the two markers were signiﬁcantly higher in
MPM patients than in hydrothorax or asbestos exposure groups (P< 0.0001), however the difference
between MPM and Mets group was not signiﬁcant. Combining the data from blood mesothelin and(W.M. Ashour).
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122 W.M. Ashour et al.osteopontin using logistic regression model raised the area under the ROC curve (AUC) from 0.774 for
serum mesothelin and 0.828 for plasma osteopontin to 0.867 to differentiate MPM from hydrothorax
and asbestos exposed subjects.
Combining the diagnostic capability of both pleural markers raised the AUC from 0.871 for pleural
mesothelin and 0.847 for pleural osteopontin to 0.905 to differentiate MPM from hydrothorax patients.
Conclusion: The performance of serum and pleural mesothelin in diagnosing MPM was improved
when combined with plasma and pleural osteopontin (respectively) through logistic regression analysis
model. This will be a great advance in screening and management of MPM.
ª 2012 The Egyptian Society of Chest Diseases and Tuberculosis. Production and hosting by Elsevier B.V.
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Malignant pleural mesothelioma (MPM) is a highly aggressive
tumor with poor survival rate. The latency period between ﬁrst
exposure to asbestos and the development of mesothelioma
has a wide range with an average of 15–40 years. The median
survival time after diagnosis is less than18 months [1]. World-
wide, the incidence of MPM has increased and is expected to
increase for at least the next 10 years as a result of widespread
exposure to asbestos in past decades [2].
Management of patients with MPM remains difﬁcult as
they are often referred in a late stage. Moreover MPM
exhibits high resistance to radiotherapy and chemotherapy
[3]. Therefore the discovery of a serum marker that permits
earlier diagnosis or can accurately predict response to treat-
ment will be a great advance in the management of this
malignancy [4].
Several reports have raised interest about soluble mesoth-
elin [2,3,5] and osteopontin [4] as possible markers for diag-
nosing MPM. However questions were raised about the
clinical utility of these markers because the early reports
did not include other pleural malignancies and non malig-
nant pleural disease as controls [4,6]. Mesothelin is a phys-
iologically expressed membrane-bound peptide on the
surface of normal mesothelial cells and is found expressed
in various cancers, including MPM, pancreatic, ovarian can-
cers, sarcomas, and in some gastrointestinal and pulmonary
Carcinoma [7]. A soluble form released from the membrane-
bound mesothelin can be detected in blood, and have been
found highly increased in the blood of mesothelioma pa-
tients [2,5].
Osteopontin is an extra cellular adhesion protein involved
in non-mineral bone matrix formation, and is a key cytokine
in mediating type 1 immune response [8]. Osteopontin is also
a regulator of inﬂammation, regulator of macrophage differen-
tiation and recruitment, and is implicated in potentiating met-
astatic spread of tumor cells [9]. In fact osteopontin was ﬁrst
described as being secreted by transformed malignant epitheli-
oid cells [10].
Aim of work
The aim is to evaluate the diagnostic value of soluble mesoth-
elin and osteopontin levels in blood and pleural ﬂuid of meso-
thelioma patients so as to assess whether combination of these
markers can provide additional diagnostic value to the existing
conventional diagnostic tools.Subjects and methods
Starting from January 2008 till March 2010, 62 patients were
recruited whose diagnosis was consistent with mesothelioma.
They were admitted in Chest Diseases Department in Kasr
Al-Aini hospital, Cairo University. All these patients had chest
pain, dyspnea associated with pleural thickening and or pleural
effusion on thoracic computed tomography scan. Pleural biop-
sies were taken by thoracoscopy, thoracotomy or US guided
biopsy for ﬁnal histo-pathological diagnosis. Exclusion criteria
were any concomitant infectious or suppurative lung disease.
Based on the histo-pathological diagnosis the 62 patients were
divided into 2 groups: Group 1: 38 patients with conﬁrmed
MPM; Group 2: 24 patients with pleural metastases (Mets)
of various carcinomas.
We also included 29 patients with hydrothorax as Group 3.
The pleural ﬂuid was conﬁrmed to be non-malignant by
cytology.
Group 4: By the aid of the occupational disease physicians,
we recruited 32 healthy subjects living, for at least 10 years, in
a residential area (AlMaasara) that surrounds one of the well
known asbestos factories in Helwan, Cairo. Subjects were re-
cruited from the houses facing the factory. Those subjects were
supposed to be environmentally exposed to asbestos. They had
no clinical complaint, no chest or any systematic disease and
none of them developed MPM or another malignancy. Only
serum samples were available from this group.
Informed consent was obtained from all participants.
Sampling
Blood samples (EDTA- anticoagulated plasma for osteopontin
and serum for mesothelin assay) were collected from all partic-
ipants. Also pleural samples (if available) were collected for
both markers assay. From 123 participants, 197 samples were
available (123 blood and 74 pleural samples)
Osteopontin is cleaved by thrombin after blood coagulation
and therefore serum levels of osteopontin are much lower than
the corresponding plasma levels [11,12]. Therefore we pre-
ferred to measure plasma and not serum osteopontin. Blood
and pleural ﬂuid samples were centrifuged for 10 min at
4000 rpm and the supernatant was stored in aliquots at
80 C until the time of analysis.
Soluble mesothelin assay
Serum and pleural levels of soluble mesothelin were deter-
mined using sandwich-type ELISA kit (Mesomark, Fujirebio
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instructions; results were expressed in nanomoles/L.
Osteopontin assay
Plasma and pleural levels of osteopontin were determined
using human osteopontin kit (R&D systems, Inc., Minneapo-
lis, USA) which employs the quantitative sandwich ELIZA
technique; results were expressed in ng/ml
Statistics
Quantitative non-normal data were expressed as median and
interquartile range (25–75th percentiles). Comparison between
groups was carried out using Kruskal–Wallis or Mann–
Whitney tests. Chi-square test was used to assess the differ-
ences between different variables. Linear regression analysis
was done to determine the correlation between different vari-
ables. To assess the clinical potential of each marker at a time,
receiver operating characteristic (ROC) curves were plotted,
and the areas under curves (AUC) were calculated with their
95% conﬁdence intervals (95% CI) using standard techniques
to evaluate sensitivity and speciﬁcity. Logistic regression anal-
ysis was run to calculate the probability of MPM diagnosis
using different combinations of blood and pleural levels of
mesothelin and osteopontin .ROC curves for the combinations
of markers were plotted with calculation of the AUC and the
best cut-off values. Statistical analysis was run on SPSS for
Windows, release.17.0 (SPSS Inc., Chicago, Ill, USA). P values
60.05 were considered statistically signiﬁcant.
Results
Demographic and laboratory data of the studied groups are
summarized in Table 1.Table 1 Demographic data and levels of mesothelin and osteopont
MPM group n= 38
(for serum markers)
n= 26 (for pleural markers)
Mets group
Age (years) Median (25–75th) 56(44–64) 58 (50–70)
Gender
Male n (%) 27 (71%) 9 (37%)




Duration of exposure in
years Median (25–75th)
41 (26–58) –
Primary disease n (%) Epithelioid 17 (45%) Bronchogen
Mixed 11 (29%) Breast 8 (34
Sarcomatoid 10 (26%) Unknown 2
Serum mesothelin (nmol/L) 1.1 (0.6–2.7)a 0.7 (0.3–1.7
Pleural mesothelin (nmol/L) 5.8 (2.5–18.6)a 4.7 (0.6–11.
Plasma osteopontin (ng/ml) 126 (81–200)a 94 (47–170)
Pleural osteopontin (ng/ml) 2135 (218–2802)a 490 (150–15
Blood and pleural levels are presented as Median and percentiles (25–75t
a,ab,b,c Groups comparing bearing same initials do not differ statisticallyDiagnostic value of serum mesothelin
MPM group showed the highest median level of serum mes-
othelin (1.1 nmol/L). Serum mesothelin had a good capability
to distinguish MPM from hydrothorax and asbestos exposure
groups with AUC of 0.785 and 0.752, respectively, although it
showed low capability in differentiating MPM from Mets
group (AUC 0.577) (Table 2). Mesothelin level at 0.55 nM
was determined to be the optimal cutoff value with a sensitivity
of 79% and speciﬁcity of 60% for the diagnosis of
mesothelioma.
Diagnostic value of pleural mesothelin
In the three groups of patients having pleural samples pleural
mesothelin levels were higher than respective serum values (Ta-
ble 1). Pleural mesothelin median value was highest in MPM
group (5.8 nmol/L). Pleural mesothelin showed its best dis-
criminating power when ROC curve was drawn for differenti-
ating MPM from hydrothorax group as AUC was 0.871.The
optimal cutoff value was 3.0 nmol/L with 73% Sensitivity
and 82% speciﬁcity. Pleural mesothelin had better diagnostic
value than serum mesothelin as all its AUCs were better than
corresponding serum mesothelin AUCs among different com-
parisons (Table 2).
Diagnostic value of plasma osteopontin
The highest median level was found in MPM group (126 ng/
ml). Serum osteopontin had an excellent ability to distinguish
between MPM and asbestos exposure groups with AUC of
0.943 (Table 2).
Plasma osteopontin showed signiﬁcant positive correlation
with the duration of asbestos exposure (r= 0.48, P= 0.005)







15 (52%) 22 (69%)
14 (48%) 10 (31%)
– 32 (100%)
– 20 (15–25)
ic 14 (58%) Liver cirrhosis 21 (72%) –
%) Collagen disease 6 (21%)
(8%) Heart failure 2 (7%)
)ab 0.2 (0.1–0.8)b 0.5 (0.4–0.9)b <0.0001
8)a 0.7 (0.4–2.7)b – <0.0001
ab 82 (44–144)b 34 (29–57)c <0.0001
04)a 81 (35–417)b – <0.0001
h).
at P< 0.05.
Figure 1-A Plotted concentrations of serum mesothelin and plasma osteopontin levels in 38 patients with MPM (closed diamonds), 29
hydrothorax and 32 asbestos-exposed individuals (open diamonds). Cut-off values for each assay are designated by lines.













Serum mesothelin 0.785 0.752 0.577 0.774 0.685 0.689 0.746
(0.656–0.915) (0.639–0.865) (0.413–0.741) (0.678–0.852) (0.566–0.805) (0.584–0.794) (0.671–0.875)
Pleural mesothelin 0.871 – 0.648 – 0.764 – 0.802
(0.778–0.964) (0.488–0.808) (0.658–0.870) (0.703–0.902)
Plasma Osteopontin 0.698 0.943 0.681 0.828 0.690 0.880 0.619
(0.556–0.841) (0.890–0.995) (0.528–0.835) (0.739–0.897) (0.568–0.812) (0.807–0.952) (0.484–0.753)
Pleural Osteopontin 0.847 – 0.665 – 0.760 – 0.794
(0.738–0.956) (0.511–0.819) (0.640–0.879) (0.691–0.897)
a Non-malignant groups includes: hydrothorax and asbestos exposure groups
b Malignant groups includes: MPM and Mets.
124 W.M. Ashour et al.nient cutoff value was 73 ng/ml with 84% sensitivity and 72%
speciﬁcity in conﬁrming mesothelioma
Diagnostic value of pleural osteopontin
The highest median level of pleural osteopontin was recorded
in the MPM group (2135 ng/ml). Pleural osteopontin showed
its best differentiating capability between MPM and hydrotho-
rax groups with AUC of 0.847 (Table 2). At a cutoff value of
720 ng/ml, pleural osteopontin had a sensitivity of 73% and
speciﬁcity of 88% for the diagnosis of mesothelioma.
Combining mesothelin and osteopontin
A) Combining serum mesothelin and plasma osteopontin. A
bivariate scatter plot of serum mesothelin vs plasma osteopon-
tin levels in MPM, hydrothorax and asbestos exposure subjectsrevealed that 35% of patients were positive for both markers,
20% were positive for only mesothelin, 14% were positive for
only osteopontin, and 31% were negative for both markers
(Fig. 1-A).So both markers were concordant in 66% of those
3 groups of patients.
The probability of the risk of developing MPM was calcu-
lated using logistic regression formula
Logit (P) = (0.628X1) + (0.015X2)  2.645. Where
X1 = serum mesothelin and X2 = plasma osteopontin. Logit
(P) was converted into probability of the risk by using the fol-
lowing equation: P ¼ 1
1þelogitðPÞ. According to this formula the
AUC of the ROC curve of combined markers was increased
from 0.774 for serum mesothelin and from 0.828 for plasma
osteopontin to 0.867. Also the combination of these two blood
markers had a better performance in terms of sensitivity
(which was raised from 79% for serum mesothelin to 84%)
Figure 1-B Plotted concentrations of Pleural mesothelin and pleural osteopontin levels in 26 patients with MPM (closed diamonds) and
29 hydrothorax patients (open diamonds). Cut-off values for each assay are designated by lines.
Table 3 Sensitivity, Speciﬁcity and AUC of each marker and after combination.
Markers Sensitivity (%) Speciﬁcity (%) AUC (95%CI)
Serum mesothelin (cutoﬀ point 0.55 nmol/L) 79 60 0.774 (0.678–0.852)
plasma osteopontin (cutoﬀ point 73 ng/ml) 84 72 0.828 (0.739–0.897)
Combined blood markers (when cutoﬀ combined probability of risk >0.313) 84 79 0.867 (0.784–0.927)
Pleural mesothelin (cutoﬀ point 3.0 nmol/L) 73 82 0.871 (0.778–0.964)
pleural osteopontin (cutoﬀ point 720 ng/ml) 73 88 0.847 (0.738–0.956)
Combined pleural markers (when cutoﬀ combined probability of risk >0.559) 77 88 0.905 (0.789–0.969)
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entiating MPM from hydrothorax and asbestos exposed sub-
jects (Fig. 2-A, Table 3).
B) Combining pleural mesothelin and pleural osteopontin. A
bivariate scatter plot of pleural mesothelin vs pleural osteo-
pontin levels in MPM (only patients with pleural effusion)
and hydrothorax patients revealed that 29% of patients were
positive for both markers, 18% were positive for only pleural
mesothelin, 14% were positive for only pleural osteopontin,
and 39% were negative for both markers (Fig. 1-B). So both
pleural markers were concordant in 68% of those two groups
of patients.
The probability of the risk of developing MPM was calcu-
lated using logistic regression formula:
LogitðPÞ ¼ ð0:416X1Þ þ ð0:007X2Þ  2:324
where X1 = pleural mesothelin and X2 = pleural osteopon-
tin. Logit (P) was converted into probability of the risk by
using the equation: P ¼ 1
1þelogitðPÞ. The AUC of the ROC curve
of combined pleural markers was raised from 0.871 for pleural
mesothelin and from 0.847 for pleural osteopontin to 0.905 indifferentiate MPM from hydrothorax group. Combined sensi-
tivity yielded a higher percentage (77%) than either marker
alone. the speciﬁcity was raised from 82% for pleural mesoth-
elin to 88% for combined pleural markers (Fig. 2-B, Table 3)
Discussion
Soluble mesothelin remains the best available biomarker for
MPM [13]. However the lack of sensitivity for early stage dis-
ease provides a motivation for the search of an additional mar-
ker that could be combined with mesothelin for early
malignancy detection.
In agreement with other reports [2,5,7], we conﬁrmed here
that serum mesothelin level is signiﬁcantly higher in MPM pa-
tients than in subjects exposed to asbestos (P< 0.0001) or
those with hydrothorax (P< 0.0001), but was insigniﬁcantly
higher than in Mets group (P 0.0001).
When we tried to optimize both sensitivity and speciﬁcity of
serum mesothelin, the best cutoff value was 0.55 nM with 79%
sensitivity and 60% speciﬁcity. In concordance with our results
portal et al. [14] chose 0.55 nmol/L to be the best cutoff level of
serum mesothelin with 72% sensitivity and 72% speciﬁcity.
Figure 2-A Multiple ROC curve for serum mesothelin, plasma osteopontin and combination of both blood markers. AUCs were
determined for each marker comparing MPM vs hydrothorax and asbestos exposed subjects.
Figure 2-B Multiple ROC curve for pleural mesothelin, pleural osteopontin and combination of both pleural markers. AUCs were
determined for each marker comparing MPM vs hydrothorax group.
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speciﬁcity (80% and 82%, respectively) at different cutoff va-
lue which was 0.93 nmol/L. To achieve similar speciﬁcity, we
had to set the cutoff at 0.95 nmol/L but this resulted in only
50% sensitivity.
On the basis of our study the use of serum mesothelin alone
as MPM screening marker may not reach sufﬁcient sensitivity
with adequate speciﬁcity. To reach a sensitivity of >90–95%,
the cut off value would be 0.25 nmol/L (sensitivity 96%), again
the speciﬁcity would fall down to 56%. However, established
tumor markers such as prostate speciﬁc antigen (PSA) exhibit
similar or even lower test performances; PSA has sensitivity for
detecting prostate cancer of 75% but a low speciﬁcity of only
40%, even if the identiﬁcation of other molecular forms of
PSA has led to a new era in PSA markers [15].
Given that the majority of MPM patients present with exu-
dative effusions [3], we investigated whether mesothelin levels
in effusions would add to the diagnostic value of serum mes-
othelin levels. In the current study pleural mesothelin levelabove 3.0 nmol/L is highly suggestive of MPM (73% sensitiv-
ity and 82% speciﬁcity) with a resulting AUC of 0.871 when
differentiating MPM from hydrothorax group. This result is
very similar to that reported by Scherpered et al. [2] who gen-
erated a ROC curve for pleural mesothelin in the setting of
MPM diagnosis in a multicentre study in France with an
AUC of 0.831.
Creaney et al. [13] showed a better AUC (0.890) for pleural
mesothelin to diagnose MPM. This concordance of the results
from these independent studies is promising for the future use
of pleural mesothelin in diagnosing pleural effusions. Notably
we have also shown that pleural mesothelin had AUCs higher
than that of serum mesothelin among our different compari-
sons. This further underlines the fact that measurement of
effusion mesothelin is a useful diagnostic test. However nega-
tive results should be interpreted cautiously as it does not rule
out malignancy.
In fact, not all patients with mesothelioma present with an
effusion, so the measurement of a serum biomarker such as
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such patients.
When measuring plasma osteopontin our results were con-
sistent with Pass et al. [4] and Grigoriu et al. [7] studies who
reported that signiﬁcant higher levels of plasma osteopontin
were recorded in MPM patients than asbestos exposure group.
In our study, ROC analysis comparing MPM group with
asbestos exposure subjects showed an excellent ability of plas-
ma osteopontin (AUC= 0.943) in differentiating between the
two groups.
However the utility of plasma osteopontin alone is ham-
pered by the insufﬁcient speciﬁcity to MPM as osteopontin
was found to be elevated in other types of cancers including
gastrointestinal, laryngeal, and urinary neoplasms which
would result in a very high number of false positive results
[4]. Osteopontin is also a cytokine that has been involved in
a broad range of biological processes as cellular immune re-
sponse and inﬂammation, cancer progression and metastases
[16]. Moreover in our results signiﬁcant positive correlation
was found between the duration of exposure and plasma oste-
opontin among the asbestos exposed subjects (r= 0.488,
P= 0.005). This means that the level of osteopontin is affected
by the ongoing inﬂammatory process along the years of expo-
sure, however serum mesothelin did not show this positive cor-
relation with the duration of exposure in asbestos exposed
subjects(r= 0.194; P= 0.50). This could be an advantage of
mesothelin over osteopontin as it is not easily cleaved from
the surface of mesothelial cells by the inﬂammatory process
and there is something particular about the malignant state
to increase mesothelin level. This is in contrast to other mark-
ers such as CA125 and CA19-9 which are also released by nor-
mal mesothelial cells and are increased in inﬂammatory states,
reducing their diagnostic speciﬁcity for MPM [17].
There is considerable interest in screening asbestos exposed
individuals for the early detection of MPM. Combining mark-
ers often improves the performance of diagnosis and screening
strategies, and the use of independent biomarkers can signiﬁ-
cantly enhance sensitivity [18]. However, several reports failed
to present suitable combination of markers that is able to in-
crease diagnostic accuracy of mesothelin [19–21].
Cristaudo et al. [22] in their recent report mentioned that
their study was the ﬁrst to show that combined serum mesoth-
elin and plasma osteopontin through logistic regression analy-
sis can increase both the sensitivity and speciﬁcity. And here
we also succeeded to show higher sensitivity, speciﬁcity and
higher AUC by calculating the probability of risk through lo-
gistic regression analysis. We also add here that combination
of pleural levels of mesothelin and osteopontin increased the
sensitivity and the AUC for diagnosing MPM.
Usually, the application of the two traditional ways of com-
bining multi-tests (parallel assessment or serial assessment) im-
proves either sensitivity or speciﬁcity. However estimation of
the sensitivity and speciﬁcity after calculation of the probabil-
ity of risk through logistic regression analysis avoided this
limitation.Conclusion
Combined blood mesothelin and osteopontin measurement
improved the diagnostic ability of serum mesothelin in terms
of sensitivity, speciﬁcity and AUC. Pleural mesothelin is abiological marker as interesting as serum mesothelin and is
potentially better. Until now the measurement of tumor mark-
ers in pleural effusions has not been part of routine clinical
practice. The data presented here argue that measurement of
pleural mesothelin and osteopontin might be a useful adjunct
to serum analysis in patients with suspected malignancy, par-
ticularly if the index of suspicion for mesothelioma is high.
As effusion ﬂuid is routinely sent for pathological and bio-
chemical analysis, it is simple to undertake mesothelin and
or osteopontin analysis at the same time and not to be satisﬁed
with blood level only.
Additional investigations in a larger panel or maybe multi-
centre study will be necessary to demonstrate the usefulness of
blood and pleural mesothelin and osteopontin combination in
the management of MPM.
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